Trovagene Inc. (NASDAQ:TROV) was up 3.1% during mid-day trading on Friday . The company traded as high as $5.27 and last traded at $5.24, with a volume of 242,486 shares traded. The stock had previously closed at $5.08.

A number of equities research analysts recently issued reports on TROV shares. Avondale Partners reiterated a “market perform” rating and set a $6.00 target price on shares of Trovagene in a research report on Tuesday, March 29th. Cantor Fitzgerald reiterated a “buy” rating and set a $10.00 target price on shares of Trovagene in a research report on Monday, March 28th. Piper Jaffray Cos. cut shares of Trovagene from an “overweight” rating to a “neutral” rating and increased their target price for the stock from $5.26 to $8.00 in a research report on Monday, April 25th. Leerink Swann lowered shares of Trovagene from an “outperform” rating to a “sector perform” rating in a report on Tuesday, April 26th. Finally, Argus lowered shares of Trovagene from a “buy” rating to a “hold” rating in a report on Thursday, April 28th. Seven equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $6.96.

The firm’s market cap is $150.50 million. The stock’s 50-day moving average is $4.76 and its 200 day moving average is $4.77.

Trovagene (NASDAQ:TROV) last announced its earnings results on Tuesday, May 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.29) by $0.07. On average, equities research analysts expect that Trovagene Inc. will post ($1.30) earnings per share for the current fiscal year.

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.